




The ACT Consortium and the Centralized Drug Safety Repository

RBM CMWG-7, Annecy, France

Cheryl Pace March 2013




The ACT Consortium is an international research collaboration aiming to maximize the public health impact of artemisinin-based combination therapy (ACT) through high quality, policy driven, multidisciplinary research




Funded by the Bill and Melinda Gates Foundation









Methods for evaluating harm associated with antimalarial drugs

A C T CONSORTIUM

1) Mixed-method study in two antimalarial drug safety trials¹

Optimal methods for collecting harms data unclear
 Evidence that questioning methods influence outcomes
 (participant-reported AEs, previous & concomitants meds etc.)

2) Survey with antimalarial drug clinical researchers


- Range of methods used to elicit, assess (for severity/causality) and record AEs and related data could impact on ability to pool data (preliminary results)

3) Cochrane systematic review

- Eliciting adverse effects data from participants in clinical trials

4) Delphi

- Reflect on above & work towards consensus on whether, and if so how, there could be harmonisation as to appropriate methods and/or tools used




¹Allen et al. Eliciting harms data from trial participants: how perceptions of illness and treatment mediate recognition of relevant information to report. Trials 2011, 12(Suppl. 1):A10. Oral Presentation.

Non-clinician data capture forms




Established drug safety surveillance systems have limited effectiveness and in low resource settings, treatment provision is often undertaken by non-clinicians



Davies EC, Chandler CIR, Innocent SHS, Kalumuna C, Terlouw DJ, et al. (2012) Designing Adverse Event Forms for Real-World Reporting: Participatory Research in Uganda. PLoS ONE 7(3): e32704. doi:10.1371/journal.pone.0032704







The efficacy, safety and pharmacokinetics of artemether-lumefantrine for the treatment of uncomplicated malaria in Tanzanian adults receiving first-line antiretrovirals: a clinical controlled study (InterACT) (nevirapine or efavirenz)

Vestergaard L, Lemnge M, Bygbjerg I et al

Study Groups	Description
Group A	HIV +ve, ARVs, malaria +ve
Group B	HIV +ve, no ARVs, malaria +ve
Group C	HIV –ve, malaria +ve
Group D	HIV +ve, ARVs, malaria -ve


Pharmacokinetic interaction between the antimalarial combination artemetherlumefantrine and combination antiretroviral therapy including nevirapine in HIVinfected adults (SEACAT)

Barnes K, Kredo T et al

Study Groups	Description
Group A	HIV +ve, ARVs, malaria –ve
Group B	HIV +ve, no ARVs, malaria –ve


© The Liverpool School of Tropical Medicine






MiP Consortium

Aim: To identify & evaluate new ways of preventing and treating malaria in pregnancy to improve the evidence base for its control







ACTia: safety and effectiveness of ACTs with repeated use in programmatic settings (Malawi)



- Safety of repeated treatment in young children with artemetherlumefantrine vs DHA-piperaquine over 3 years
- Phase IV effectiveness trial, real life
 - Weight-based dosing as per recommended regimen
 - Only 1st treatment observed adherence

Main research questions

Safety of repeated Rx	 Remaining concern ototoxicity Pharmacovigilance model Phase IV AE detection by clinician and non-clinical fieldworkers
Effectiveness vs efficacy	 DHA-PPQ vs artemether-lumefantrine Difference in malaria incidence? Adherence tool Rapidly changing background burden

Lalloo D, Phiri K, Terlouw D et al.


PRIME – Evaluating the impact of enhanced health facility-based care vs standard care for malaria and febrile illnesses (Uganda)



- AE monitoring of cohort over 18 months
- Artemether-lumefantrine
- Monthly household visits
- AE detection by fieldworkers (reviewed by clinicians)

Staedke S, Kamya M, Dorsey G et al







Collaboration between the ACT Consortium and MiP Consortium





Aim

 To collect and collate safety data from a variety of sources to inform on the incidence of known adverse reactions and identify new signals of potential harms



Anti-malarial specific dataset

Approx. 2000 case reports of serious adverse events

Strengthen in-country pharmacovigilance capacity

• Infrastructure developed to facilitate reporting of events to national centres

Diverse dataset

- Trials
 - Observational/Interventional studies
- Prevention vs treatment
- Clinician vs non-clinician reporting

Aggregation of data

Increased power to detect signals and inform on known harms



Integrated standardized dictionaries to aid data retrieval, presentation and analysis

- MedDRA (Medical Dictionary for Regulatory Activities)
- WHO Drug Dictionary

Ability to use Standardized MedDRA Queries

- To aid identification and retrieval of potentially relevant individual case safety reports
 - e.g. using 'extrapyramidal syndrome' SMQ to identify case reports that may be relevant to emerging signal with AS-AQ

In-depth analysis of sub-groups to identify risk factors

• Dose to onset time, age, concomitant drugs

•The Gambia (21) •Mali (40)

•Mali (40)

•Kenya (80)

•Uganda (105)

•Malawi (301)

Tanzania (144)

•Zambia (105)

Mozambique (260)

- •Burkina Faso (63)
- •Ghana (135)
- •Gabon (98)
- •Benin (288)

- •India (13)
- Afghanistan
- South Africa
- •Papua New Guinea (262) •Indonesia

Countries (no. of serious reports)

19





pregnancy









Data	A C T malaria in pregnancy CONSORTIUM
Drug	No. of serious cases (possibly/probably related to drug)
Amodiaquine-artesunate	54 (9)
Artemether-lumefantrine	224 (12)
Artesunate-SP	8 (0)
Azithromycin-SP	137 (0)
Chloroquine-SP	125 (2)
Dihydroartemisinin-piperaquine	188 (9)
Mefloquine	440 (19)
Mefloquine-artesunate	60 (7)
Sulphadoxine-pyrimethamine	351 (1)
Blinded	328 (7)
Total	1915 (66)

Acknowledgements



Funding Bill and Melinda Gates Foundation

ACT Consortium

Secretariat All PIs and study teams

LSTM/University of Liverpool

David Lalloo Munir Pirmohamed Anja Terlouw MiP Consortium

Contacts

Cheryl Pace (PV Pharmacist) <u>cpace@liverpool.ac.uk</u> +44 (0) 151 705 3358

Prof David Lalloo (PI) dlalloo@liverpool.ac.uk +44 (0) 151 705 3179

Prof David Schellenberg (Chair ACTc) David.Schellenberg@lshtm.ac.uk +44 (0)207 927 2935